Collagen stimulation in pre-aging protocols: Ellansé opportunities for patients aged 28–38

 

Aesthetic medicine is developing a new paradigm for working with younger patients. While the 28-38 age group was previously primarily viewed as a target for minimal corrections or skincare procedures, today they are increasingly becoming the target of a strategic approach—so-called pre-aging—that involves early, preventative interventions to address changes in tissue quality and maintain the skin's functional characteristics.

At the same time, the Skin Longevity strategy is actively developing, with procedures aimed at maximizing skin health and youthfulness at the biological level. This transformation in approaches to anti-aging management is largely due to both changing patient expectations and the evolution of injectables.

From instant correction to a long-term rejuvenation strategy

After age 25, collagen begins to gradually lose its structure, so a cosmetologist's primary goal is to properly monitor skin quality. Decreased fibroblast activity, changes in the architecture of the extracellular matrix, and an imbalance in the ratio of different collagen types—these processes occur gradually, but they determine further loss of elasticity, the formation of wrinkles, and the progression of ptosis.

This is why modern protocols are increasingly shifting their focus from purely volumetric correction to techniques aimed at maintaining tissue quality and more gradual remodeling of the dermis.

Collagen stimulation as part of a pre-aging strategy

Modern injection technologies in pre-aging are increasingly focused not only on volume restoration but also on stimulating neocollagenesis. Restoring the quality of the collagen matrix is considered a key factor in maintaining tissue youthfulness. This is achieved through the use of products with a prolonged biostimulating effect.

 

My default image

 
One of the products being considered within this approach is Ellansé , a polycaprolactone (PCL)-based dermal filler that combines tissue volumization with long-term collagen stimulation. Depending on the formulation (Ellansé S or Ellansé M), the clinical effect can last up to 18–24 months.

Ellansé's dual mechanism of action: immediate volumization and prolonged collagen stimulation

The Ellansé biostimulator has a secondary mechanism of action:
Ellansé biostimulant has a dual mechanism of action:

  • instant volumization is achieved through a gel based on carboxymethyl cellulose;
  • prolonged stimulation of collagen formation - due to polycaprolactone.


According to the mechanism of action of the drug, Ellansé promotes the formation of a collagen matrix and stimulates the synthesis of collagen types I and III, which can maintain the qualitative characteristics of the skin - its density, elasticity, and firmness.

How is controlled collagen stimulation achieved?

The morphology of polycaprolactone microspheres is particularly noteworthy in this context. The smooth spherical shape of the particles and their size play a key role in uniform distribution of the drug in tissues and local biological response. Biodegradation of the microspheres occurs gradually, and the duration of the clinical effect can reach two years, depending on the drug modification and individual patient characteristics.

Clinical significance for practice

For clinical practice, this means the opportunity to consider such products not only as a means of correcting volume deficits, but also as one option in protocols that prioritize natural results, gradual changes, and skin quality. For patients, this means, first and foremost, that this isn't a one-size-fits-all solution, but rather one of several possible tools that can be discussed within an individualized treatment plan.

However, pre-aging should not be considered a one-size-fits-all approach for all patients aged 28–38. The appropriateness of injection procedures, the choice of medication, and the expected outcome are determined individually, depending on the clinical situation, tissue condition, and correction goals.

Today, the effectiveness of collagen-stimulating protocols is determined not only by the drug's characteristics but also by the level of clinical expertise surrounding it. This is why companies investing in professional education and the development of the medical community are becoming increasingly important. In Ukraine, this area is actively supported by Emet, the official distributor of aesthetic medicine products . Along with introducing new solutions to the market, it is developing educational initiatives for cosmetologists and aesthetic medicine doctors within the Emet Medicine platform.

Add a comment

captcha

RefreshRefresh